Supporting Information

14-Residue Peptaibol Velutibol A from *Trichoderma velutinum* of the Himalayan Cold Habitat with Cytotoxic and Anti-tubercular Activity.

Varun Pratap Singh,^{a,b} Anup Singh Pathania,^c Manoj Kushwaha,^d Samsher Singh,^e Vandana Sharma,^{d,g} Fayaz Malik,^c Inshad Khan,^{e,f} Anil Kumar,^b Deepika Singh,^{*,a,d} and Ram A. Vishwakarma^{*,a}

^a Medicinal Chemistry Division, CSIR-Indian Institute of Integrative Medicine, Canal Road, Jammu 180 001, India

^b Department of Biotechnology, Faculty of Sciences, Shri Mata Vaishno Devi University, Katra, Jammu and Kashmir 182320, India.

^c Pharmacology Division, CSIR-Indian Institute of Integrative Medicine, Canal Road, Jammu 180 001, India

^d Quality Control and Quality Assurance Division, CSIR-Indian Institute of Integrative Medicine, Canal Road, Jammu 180 001, India

^e Clinical Microbiology Division, CSIR-Indian Institute of Integrative Medicine, Canal Road, Jammu 180 001, India

^f Department of Microbiology, Central University, Rajasthan 305 817, India

^g Academy of Scientific and Innovative Research, Jammu 180001, India

RTable of content

S.	Contents	Pages
<u>No.</u>	Fig. S1 : UDLC abromatogram of anuda axtract abouting for 15 frontions	4
1	Fig. S1. HFLC chromatogram for purification of compound 1 and 2	4
2	Fig. S2. HPLC chromatogram for re-purification for compound 3 and 4	4 5
3	Fig. S5. HPLC chromatogram for re-purification for compound 5 and 4.	5
+ 5	Fig. 54. HINNE of compound 1 in DMSO d_c at 400 MHz	0
5	Fig. 55. If NMK of compound 1 in DMSO- a_b at 400 MHz (6.8 \pm 0.0 ppm)	7
0 7	Fig. S5a: Expanded 11 NMR of compound 1 in DMSO- a_0 at 400 MHz (0.0 = 9.0 ppm)	8
8	Fig. S50: Expanded ¹ H NMR of compound 1 in DMSO- a_b at 400 MHz (0.0 – 2.6 ppm)	8
9	Fig. S6: ^{13}C NMR of compound 1 in DMSO-d ₂ at 100 MHz	9
10	Fig. S6a: Expanded ¹³ C NMR of compound 1 in DMSO-d _c at 100 MHz	9
10	Fig. S6h: Expanded ¹³ C NMR of compound 1 in DMSO- <i>d</i> ₆ at 100 MHz	10
12	Fig. S6c: Expanded ¹³ C NMR of compound 1 in DMSO-d ₆ at 100 MHz	10
12	Fig. Soc. Expanded \sim C (With of compound 1 in DMSO d_0 at 100 MHz	11
14	Fig. S7a: Expanded DEPT-135 NMR of compound 1 in DMSO-d ₆ at 100 MHz	11
15	Fig. S8: DEPT-90 NMR of compound 1 in DMSO-d ₆ at 100 MHz	12
16	Fig. S9: COSY spectrum of compound 1 in DMSO- d_6 at 400 MHz for ¹ H NMR	13
17	Fig. S9a: Expanded COSY spectrum of compound 1 in DMSO- <i>d</i> ₆ at 400 MHz for ¹ H NMR	14
18	Fig. S9h: Expanded COSY spectrum of compound 1 in DMSO- <i>d</i> ₆ at 400 MHz for ¹ H NMR	15
19	Fig. S10: TOCSY spectrum of compound 1 in DMSO- d_6 at 400 MHz for ¹ H NMR	16
20	Fig. S10a: Expanded TOCSY spectrum of compound 1 in DMSO- d_6 at 400 MHz for ¹ H	17
20	NMR	1,
21	Fig. S11: NOESY spectrum of compound 1 in DMSO- d_6 at 400 MHz for ¹ H NMR	18
22	Fig. S11a: Expanded NOESY spectrum of compound 1 in DMSO- <i>d</i> ₆ at 400 MHz for ¹ H	19
	NMR	
23	Fig. S11b: Expanded NOESY spectrum of compound 1 in DMSO- d_6 at 400 MHz for ¹ H	20
	NMR	
24	Fig. S12: HMBC spectrum of compound 1 in DMSO- <i>d</i> ₆ at 400 MHz for 'H NMR	21
25	Fig. S12a: Expanded HMBC spectrum of compound 1 in DMSO- d_6 at 400 MHz for ¹ H	22
	NMR	
26	Fig. S12b: Expanded HMBC spectrum of compound 1 in DMSO- <i>d</i> ₆ at 400 MHz for ¹ H	23
07		24
27	Fig. S13: HSQC spectrum of compound 1 in DMSO- <i>d</i> ₆ at 400 MHz for ¹ H NMR and using	24
20	DEPT 135 for fl.	25
28	Table S1: 2D-COSY, TOCSY and NOESY correlations of 1 at 400MHz for 'H NMK.	25
29	Table S2 : 2D-HMBC correlations of I at 400 MHZ for ¹ H NMR and 100 MHZ for ¹³ C NMR	27
30	Fig. S14: Martey's analysis of I using LCMS	29
31	Fig. S15: HPLC purity of compound 1.	30
32	Fig. S16: UV-spectrum of compound 1.	31
33 24	Fig. S17: IK spectrum of compound 1 in $CHCI_3$	32
34 25	Fig. 510: HPLC chromatogram of 2	33 24
33 26	Fig. 519: HKMS 01 2 Fig. 520a: MS/MS of compound 2 for $w = 1414,0020$ [M+11]+	34 25
30 27	Fig. 520a: MS/MS of compound 2 for $m/2$ 1414.9050 [M+H] ²	35
3/ 20	Fig. S20D: MIS/MIS OI m/z 454.2001 daughter 10n b4 for compound 2. Fig. S21: HDLC abromatogram of 3	30 27
20 20	Fig. S21. HFLC chromatogram of 5	29
39 40	Fig. 524. HINIVIS UI 5. Fig. S730: MS/MS of compound 3 for $m/\pi 1/1/100/2$ [M + U] ⁺	30 30
40 41	Fig. 525a. MS/MS of m/r 1200 7363 daughter ion by for compound 2	39 40
41 1	Fig. S230. MS/MS of $m/2$ 8/8 5256 daughter ion by for compound 3.	40 //1
42 13	Fig. S23. MIS/MIS OF <i>III/2</i> 040.3230 dauginer foll 08 for compound 3.	+1 12
43 11	Fig. S27. In LC chromatogram of compound 4.	+2 13
44 15	Fig. S26. HIGHD 017. Fig. S26a: MS/MS of m/r 1/28 9191 parent ion [M+H] ⁺ for compound A	+5 11
45 46	Fig. S20a. MS/MS of $m/2$ 1910 7532 daughter ion by for compound 4.	-++ //5
47	Fig. S200. HEIC overlay chromatogram of compounds $1/2$ to compound 4 .	46
48	Fig. S28: Marfey's analysis of compound 2	47

49	Fig. S29: Extracted ion chromatograms of m/z 368, 370, 384 and 400 for compound 2	48
50	Fig. S30: Marfey's analysis of compound 3	49
51	Fig. S31: Extracted ion chromatograms of m/z 368, 370, 384 and 400 for compound 3	50
52	Fig. S32: Marfey's analysis of compound 4	51
53	Fig. S33: Extracted ion chromatograms of m/z 368, 370, 384 and 400 for compound 4	52
54	Fig. S34: Extracted ion chromatograms of m/z 382 (-ESI) for compound ^L allo-Ile, ^L Ile 2, 3	53
	and 4 using chiral LCMS	
55	Fig. S35: NMR-VT experiment performed at 298K, 308K, 318K, and 328K for compound 1	54
	in DMSO- d_6 at 400 MHz (Region $\delta 6.7 - 9.1$).	
56	Fig. S36: Anti-tubercular screening report of compound 1	55



Fig. S1: HPLC chromatogram of crude extract showing for 15 fractions



Fig. S2: HPLC chromatogram for purification of compound 1 and 2.



Fig. S3: HPLC chromatogram for re-purification for compound 3 and 4.



Fig. S4: HRMS of compound 1.



Fig. S5: ¹H NMR of compound 1 in DMSO-*d*₆ at 400 MHz



Fig. S5a: Expanded ¹H NMR of compound **1** in DMSO- d_6 at 400 MHz (6.8 – 9.0 ppm)



Fig. S5b: Expanded ¹H NMR of compound **1** in DMSO- d_6 at 400 MHz (3.0 – 4.4 ppm)



g. S5c: Expanded ¹H NMR of compound **1** in DMSO- d_6 at 400 MHz (0.0 – 2.6 ppm)



Fig. S6: ¹³C NMR of compound 1 in DMSO- d_6 at 100 MHz



Fig. S6a: Expanded ¹³C NMR of compound 1 in DMSO-*d*₆ at 100 MHz



Fig. S6c: Expanded ¹³C NMR of compound 1 in DMSO- d_6 at 100 MHz



Fig. S7: DEPT-135 NMR of compound 1 in DMSO-d₆ at 100 MHz



Fig. S7a: Expanded DEPT-135 NMR of compound 1 in DMSO-d₆ at 100 MHz



Fig. S8: DEPT-90 NMR of compound 1 in DMSO-d₆ at 100 MHz



Fig. S9: COSY spectrum of compound 1 in DMSO- d_6 at 400 MHz for ¹H NMR



Fig. S9a: Expanded COSY spectrum of compound **1** in DMSO-*d*₆ at 400 MHz for ¹H NMR



Fig. S9b: Expanded COSY spectrum of compound 1 in DMSO-*d*₆ at 400 MHz for ¹H NMR



Fig. S10: TOCSY spectrum of compound 1 in DMSO- d_6 at 400 MHz for ¹H NMR



Fig. S10a: Expanded TOCSY spectrum of compound 1 in DMSO-*d*₆ at 400 MHz for ¹H NMR



Fig. S11: NOESY spectrum of compound **1** in DMSO- d_6 at 400 MHz for ¹H NMR



Fig. S11a: Expanded NOESY spectrum of compound 1 in DMSO-d₆ at 400 MHz for ¹H NMR



Fig. S11b: Expanded NOESY spectrum of compound 1 in DMSO-*d*₆ at 400 MHz for ¹H NMR



Fig. S12: HMBC spectrum of compound 1 in DMSO- d_6 at 400 MHz for ¹H NMR



Fig. S12a: Expanded HMBC spectrum of compound **1** in DMSO- d_6 at 400 MHz for ¹H NMR



Fig. S12b: Expanded HMBC spectrum of compound 1 in DMSO-*d*₆ at 400 MHz for ¹H NMR



Fig. S13: HSQC spectrum of compound 1 in DMSO- d_6 at 400 MHz for ¹H NMR and using DEPT 135 for f1.

			1	~ ~ ~ ~		
Residue		Тур е	¹ H (δ), (Mult. J in Hz)	COSY Correlations	TOCSY Correlations	NOESY Correlations
Ac	1	C=O				
	2	CH ₃	1.90, (s)			NH/Aib-1, NH/Gln-2-weak
Aib-1	1	C=O				
	2	С				
	3	CH ₃	1.34 (s)			
	4	CH3 NH	1.36 (s)* 8.73 (s)			NH/Aib-1, NH/Gln-2 $4-CH_3/Aib-1, CH_3/Ac$
Gln-2	1	C=O				
	2	CH	3.96 (m)	NH/Gln-2	3-CH ₂ , 4-CH ₂ , NH/ Gln-2	3-CH ₂ , NH/Gln-2, NH/Leu-3
	3	CH ₂	1.96 (m)	2-CH/Gln-2	2-CH/GIn-2	2-CH/GIn-2
	4	CH_2	2.29 (m), 2.18 (m)	3-CH2/GIII-2	2-CH/GIn-2	
	5	NH ₂	7.48(brs) 6.95 (brs)	Self-correlating	Self-correlating	Self-correlating
		NH	8.93 (d, 5.2)	2-CH/Gln-2	2-CH, 3-CH ₂ /Gln-2	2-CH, 3-CH ₂ /Gln-2,4-CH ₃ /Aib-1, NH/Leu-3
I 2	1	C O				
Leu-5	2	C=O CH	 4.18 (m)	 3-CH ₂ /Leu-3	 5-CH ₃ , NH/ Leu-3	 NH/Aib-4
	3	CH_2	1.78 (m), 1.47 (m)	2		2-CH, NH/Leu-3
	4	CH	1.57 (m)	5-CH ₃ /Leu-3	6-CH ₃ / Leu-3	
	5	CH_3	0.89 (d, 6.8)	4-CH/Leu-3	2-CH, 4-CH/Leu-3	
	6	CH_3	0.79 (m)*			
		NH	7.88 (d, 8.4)	2-CH/Leu-3	2-CH, 3-CH ₂ /Leu-3	2-CH, 3-CH ₂ /Leu-3, NH/GIn-2
Aib-4	1	C=O				
	2	C				
	3	CH ₃	1.49 (s)			NH/A1b-4
	4	CH3 NH	$7.93(s)^{-1}$			3-CH ₂ /Aib-4 5-CH ₂ /Pro-5
		1.11	(1)5 (5)			
Pro-5	1	C=O				
	2	CH	4.23 (m)	3-CH ₂ /Pro-5	3-CH ₂ ,4-CH ₂ , 5-CH ₂ /Pro-5	3-CH ₂ /Pro-5
	3	CH_2	2.18 (m), 2.08 (m)		2-CH/Pro-5	2-CH, 5-CH ₂ /Pro-5
	4	CH_2	1.86 (m), 1.74 (m)	A CH /Dro 5	2-CH, 5-CH ₂ /Pro-5	2-CH, 5-CH $_2$ /Pro-5 4 CH /Pro 5 NH/A;b 4 NH/Wal 6
	5	CH_2	5.08 (III), 5.58 (III)	4-CH2/F10-5	3-CH ₂ , 4-CH ₂ /F10-3	4-CH2/FI0-5, NH/AI0-4, NH/ Val-0
Val-6	1	C=O				
	2	CH	3.85 (t, 8.0)	NH, 2-CH/Val-6	3-CH, 5-CH ₃ , NH /Val-6	4-CH ₃ , NH/Val-6
	3	CH	2.18 (m)	3-CH,4-CH ₃ /Val-6	5-CH ₃ /Val-6	2-CH, NH/Val-6
	4	CH ₃	0.9/(d, 6.4)	3-CH/Val-6	2-CH, 3-CH, NH/Val-6	2-CH, NH/Val-6
	5	NH	7 28 (d. 8 4)	2-CH/Val-6	2-CH 3-CH 4-CH ₂ /Val-6	2-CH, NH/ Val-0 2-CH 3-CH 4-CH ₂ 5-CH ₂ /Val-6 5-CH ₂ /Pro-5
			,120 (d, 011)	2 012 / 11 0		
Leu-7	1	C=O				
	2	CH	4.29 (m)	NH/Leu-7	3-CH ₂ , 5-CH ₃ , NH/Leu-7	3-CH ₂ , 5-CH ₃ /Leu-7, NH/A1b-8
	3 4	CH_2	1.54 (m)	5-CH ₂ /Leu-7	2-CH/Leu-7	NH/leu-7
	5	CH ₃	0. 79 (m)*	4-CH/Leu-7	2-CH, 3-CH ₂ /Leu-7	
	6	CH ₃	0.85 (d, 6.8)			
		NH	7.21 (d, 8.4)	2-CH/Leu-7	2-CH, 3-CH ₂ /Leu-7	2-CH, 3-CH ₂ , 6-CH ₃ /Leu-7, 3-CH/Val-6
Aib-8	1	C=O				
	2	С				
	3	CH ₃	1.40 (s)			NH/Aib-8
	4	CH ₃ NH	1.29 (s) 7.63 (s)			NH/A1D-8 NH (Lett 7)
		1411	(.05 (8)			···· (Lou-/)
Pro-9	1	C=O				
	2	CH	4.13 (t, 8.4)	3-CH ₂ /Pro-9	3-CH ₂ , 5-CH ₂ /Pro-9	3-CH ₂ /Pro-9, NH/Aib-8, NH/Aib-10, NH/Aib-
	2	CU	2.20(m) 1.61 (m)		5 CIL /Dro 0	11 weak
	5 1	CH_2	2.20(m), 1.01 (m) 1.86 (m) 1.74(m)	5-CH ₂ /Pro-9	J-CH2/PTO-9 5-CH2/Pro-9	J-し口2/PTO-ソ 5CH2/Pro-9
	5		3.68(m), 3.58 (m)	4-CH ₂ /Pro-9	3-CH ₂ , 4-CH ₂ /Pro-9	NH (Aib-8)
	-		····· , ···· (····)		,	×/
Aib-10	1	C=O				
	2	CU	 1 26 (a)*			
	5 4	CH ₃	1.30 (s)* 1.36 (s)*			
	ŕ	NH	7.84 (s)			4-CH ₃ /Aib-10, 2-CH/Pro-9, NH/Aib-11

Table S1: 2D-COSY, TOCSY and NOESY correlations of **1** at 400MHz for ¹H NMR.

Aib-11	1 2 3 4	C=O C CH ₃ CH ₃ NH	 1.36 (s)* 1.44 (s) 7.34 (s)	 	 	 NH/Aib-11 3-CH ₃ /Aib-11, NH/Aib-10, NH/Aib-12
Aib-12	1 2 3 4	C=O C CH ₃ CH ₃ NH	 1.39 (s) 1.36 (s)* 7.58 (s)	 	 	 2-CH/Pro-13, 5-CH ₂ /Pro-13 5-CH ₂ /Pro-13
Pro-13	1 2 3 4 5	$\begin{array}{c} C=O\\ CH\\ CH_2\\ CH_2\\ CH_2\\ CH_2 \end{array}$	4.23 (m) 2.18(m), 2.08 (m) 1.86(m), 1.74 (m) 3.68(m), 3.58 (m)	 3-CH ₂ /Pro-13 4-CH ₂ /Pro-13	3-CH ₂ , 4-CH ₂ /Pro-13 2-CH, 5-CH ₂ /Pro-13 2-CH, 5-CH ₂ /Pro-13 3-CH ₂ , 4-CH ₂ /Pro-13	3-CH ₂ /Pro-13 5-CH ₂ /Pro-13 2-CH/Pro-13, 5-CH ₂ /Pro-13 4-CH ₂ /Pro-13
Leuol	1 2 3 4	CH CH ₂ CH CH ₃	3.77 (m) 1.37 (m) 1.67 (m) 0.82 (m)*	2-CH ₂ ,NH/Leuol 1-CH/Leuol 5-CH ₃ /Leuol	2-CH ₂ /Leuol 1-CH, 4-CH ₃ , 6-CH ₂ , NH /Leuol OH 2-CH ₂ /Leuol	NH/Leuol OH
	5 6	CH ₃ CH ₂ OH NH	0.79 (m)* 3.27(m), 3.18 (m) 7.15 (d, 9.6)	3-CH/Leuol OH 1-CH/ Leuol	2-CH ₂ , NH/Leuol 1-CH,2-CH ₂ , 6-CH ₂ /Leuol	NH/Leuol 1-CH, 2-CH ₂ /Leuol, 5-CH ₂ /Pro-13
^a From DE	EPT-	Он 135, *sig	4.25 (m) mal overlap	0-CH2/Leuoi		

Residue		Туре	$^{13}\mathrm{C}\left(\delta\right)$	¹ H (δ), (Mult. J in Hz)	HMBC Correlations
Ac	1 2	C=O CH ₃	171.2 22.9	 1.90, (s)	 CO/Ac
Aib-1	1 2 3 4	C=O C CH ₃ CH ₃ NH	176.3 55.9 23.6* 26.5	 1.34 (s) 1.36 (s)* 8.73 (s)	 CO/Aib-1 CO, 2-C, 4-CH ₃ /Aib-1, CO/Gln-2
Gln-2	1 2 3 4 5	C=O CH CH ₂ CH ₂ C=O NH ₂ NH	172.6 55.0 25.0 31.1 174.5	3.96 (m) 1.97 (m) 2.29 (m), 2.18 (m) 7.48 (br s), 6.95 (br s) 8.93 (d, 5.2)	 3-CH ₂ /Gln-2, CO/Leu-3 2-CH, 5-CO/Gln-2 4-CH ₂ , 5-CO/Gln-2 CO/Aib-1
Leu-3	1 2 3 4 5 6	C=O CH CH ₂ CH CH ₃ CH ₃ NH	171.7 51.2 39.1 ^a 24.2 22.8 20.7	4.18 (m) 1.78 (m), 1.47 (m) 1.57 (m) 0.89 (d, 6.8) 0.79 (m)* 7.88 (d, 8.4)	 5-CH ₃ /Leu-3 3-CH ₂ , 4-CH/Leu-3 5-CH ₃ /Leu-3 CO/Leu-3
Aib-4	1 2 3 4	C=O C CH ₃ CH ₃ NH	173.6 55.8 23.4 25.4	1.49 (s) 1.36 (s)* 7.93 (s)	 2-C, 4-CH ₃ /Aib-4, CO/Pro-5 2-C, 3-CH ₃ /Aib-4 2-C, 3-CH ₃ /Aib-4, CO/Leu-3
Pro-5	1 2 3 4 5	$\begin{array}{c} C=O\\ CH\\ CH_2\\ CH_2\\ CH_2\\ CH_2 \end{array}$	172.7 63.1 28.7 25.4 ^a 48.4	4.23 (m) 2.18 (m), 2.08 (m) 1.86 (m), 1.74 (m) 3.68 (m), 3.58 (m)	 CO, 3-CH ₂ /Pro-5 3-CH ₂ /Pro-5
Val-6	1 2 3 4 5	C=O CH CH CH ₃ CH ₃ NH	171.4 60.1 28.8 19.0 18.9	3.85 (t, 8.0) 2.18 (m) 0.97 (d, 6.4) 0.91 (d, 6.8) 7.28 (d, 8.4)	CO, 3-CH, 5-CH ₃ /Val-6 5-CH ₃ /Val-6 2-CH, 3-CH, 5-CH ₃ /Val-6, 2-CH, 3-CH/Val-6 CO/Pro-5
Leu-7	1 2 3 4 5 6	C=O CH CH ₂ CH CH ₃ CH ₃ NH	172.2 51.2 39.6 ^a 24.4 21.5 22.8	4.29 (m) 1.54 (m) 1.67 (m) 0.79 (m)* 0.85 (d, 6.8) 7.21 (d, 8.4)	 CO, 3-CH ₂ /Leu-7 6-CH ₃ /Leu-7 3-CH ₂ , 6-CH ₃ /Leu-7, 3-CH ₂ , 4-CH/Leu-7 CO/Val-6
Aib-8	1 2 3 4	C=O C CH ₃ CH ₃ NH	172.1 55.6 23.7* 25.6	1.40 (s) 1.29 (s) 7.63 (s)	 CO, 2-C/Aib-8 CO/Leu-7, 2-C, 3-CH ₃ /Aib-8
Pro-9	1 2 3 4 5	C=O CH CH ₂ CH ₂ CH ₂	172.9 63.2 28.5 25.1 48.1	4.13 (t, 8.4) 2.20(m), 1.61 (m) 1.86 (m), 1.74(m) 3.68(m), 3.58 (m)	 CO, 3-CH ₂ /Pro-9 3-CH ₂ /Pro-9 3-CH ₂ , 4-CH ₂ /Pro-9
Aib-10	1 2 3 4	C=O C CH ₃ CH ₃ NH	173.6 56.1 25.6 ^a 23.6*	1.36 (s)* 1.36 (s)* 7.84 (s)	 CO/Aib-10 CO/Pro-9, 2-C/Aib-10

Table S2: 2D-HMBC correlations of 1 at 400 MHz for ¹ H NMR and 100 MHz for ¹³	C NMR

Aib-11	1	C=O	175.5		
	2	CH	26.5	1 26 (a)*	
	1		20.5	$1.30(8)^{-1}$	CO/Aib 11
	4		23.0	1.44(s)	CO/AID-11
		NH		7.34 (S)	CO/AID-10, 3-CH ₃ /AID-11
Aib-12	1	C=O	171.6		
	2	С	55.7		
	3	CH_3	23.7*	1.39 (s)	CO, 4-CH ₃ /Aib-12
	4	CH_3	25.0	1.36 (s)*	
		NH		7.58 (s)	CO, 2-C, 3-CH ₃ /Aib-12, CO/Aib-11
Dro 12	1	C-0	170.0		
F10-15	2	CH	61.0	1.22 (m)	CO/Pro 12
	2	СП	201.9	4.23 (III) 2.18 (m) 2.08 (m)	CO/FI0-13
	3	CH_2	20.1	2.16(III), 2.06(III) 1.96(III), 1.74(III)	
	4	CH ₂	25.6"	1.86(m), 1.74(m)	2 CU /P 12
	5	CH_2	48.4	3.68(m), 3.58 (m)	3-CH ₂ /Pro-13
Leuol	1	CH	48.4	3.77 (m)	6-CH ₂ OH/Leuol weak
	2	CH_2	39.3ª	1.37 (m)	
	3	CH	23.8	1.67 (m)	4-CH ₃ /Leuol
	4	CH ₃	22.8	0.82 (m)*	
	5	CH ₃	20.2	0.79 (m)*	2-CH ₂ /Leuol
	6	CH_2OH	63.9	3.27(m), 3.18 (m)	1-CH, 2-CH ₂ /Leuol
		NH		7.15 (d, 9.6)	CO/Pro-13
		OH		4.23 (m)	
^a From D	EPT-1	35, *signal	overlap	× /	
		· U			



Fig. S14: Marfey's analysis of 1 using LCMS.



Sample Name Sample ID Data Filename	: B VELUTIBOL A (1) : B : B lod		
Method Filename	: 10-60 ACN63 lcm		
Batch Filename	: BATCH SAMPLE, 07-01-2019.lcb		
Vial #	: 1-47	Sample Type	: Unknown
Injection Volume	: 5 uL		
Date Acquired	: 07-01-2019 22:33:26	Acquired by	: System Administrator
Date Processed	: 07-01-2019 23:36:29	Processed by	: System Administrator
Date Acquired Date Processed	: 07-01-2019 22:33:26 : 07-01-2019 23:36:29	Acquired by Processed by	: System Administrator : System Administrator

<Chromatogram>



<Peak Table>

PDA C	h1 214nm			
Peak#	Ret. Time	Area	Height	Area%
1	43.033	307734	11855	100.000
Total		307734	11855	100.000

Fig. S15: HPLC purity of compound 1.



==== Shimadzu LabSolutions UV Spectrum ====

Fig. S16: UV-spectrum of compound 1.



Fig. S17: IR spectrum of compound **1** in CHCl₃



Sample Name Sample ID Data Filename Method Filename Batch Filename Vial # Injection Volume Date Acquired Date Processed	: B1 VELUTIBOL B (2) : B1 : B1.lcd : 10-60 ACN63.lcm : BATCH SAMPLE, 07-01-2019.lcb : 1-56 : 5 uL : 08-01-2019 09:08:28 : 08-01-2019 10:11:32	Sample Type Acquired by	: Unknown : System Administrator
Date Processed	: 08-01-2019 10:11:32	Processed by	: System Administrator

<Chromatogram>



<Peak Table>

PDA C	h1 214nm			
Peak#	Ret. Time	Area	Height	Area%
1	43.482	260648	7738	100.000
Total		260648	7738	100.000

Fig. S18: HPLC chromatogram of 2



ig. S19: HRMS of 2



Ac-Aib Gln Lxx Aib Pro Vxx Lxx Aib Pro Aib Aib Aib Pro-Lxxol

Fig. S20a: MS/MS of compound 2 for *m*/*z* 1414.9030 [M+H]⁺.



Fig. S20b: MS/MS of m/z 454.2661 daughter ion b₄ for compound **2**.



Sample Name Sample ID Data Filename Method Filename Batch Filename Vial # Injection Volume Date Acquired Date Processed	: D1 VELUTIBOL C (3) : D1 : D1.lcd : 10-60 ACN63.lcm : BATCH SAMPLE, 07-01-2019.lcb : 1-50 : 50 uL : 08-01-2019 02:47:26 : 08-01-2019 03:50:29	Sample Type Acquired by Processed by	: Unknown : System Administrator : System Administrator
Date Acquired	: 08-01-2019 02:47:26	Acquired by	: System Administrator
Date Processed	: 08-01-2019 03:50:29	Processed by	: System Administrator

<Chromatogram>



<Peak Table>

PDA Ch1 214nm				
Peak#	Ret. Time	Area	Height	Area%
1	44.332	652508	17962	100.000
Total		652508	17962	100.000

Fig. S21: HPLC chromatogram of 3



Fig. S22: HRMS of 3.

Ac-Aib - Gin - Lxx - Aib - Pro - Lxx - Aib - Pro - Aib - Aib - Aib - Aib - Pro - Lxxol



Fig. S23a: MS/MS of compound 3 for *m*/*z* 1414.9043 [M + H]⁺.



Fig. S23b: MS/MS of m/z 1200.7363 daughter ion b_{12} for compound **3**.



Fig. S23c: MS/MS of m/z 848.5256 daughter ion b₈ for compound 3.



Sample Name Sample ID Data Filename Method Filename Batch Filename	: D2 VELUTIBOL D : D2 : D2.lcd : 10-60 ACN63.lcm : BATCH SAMPLE_07-01-2019.lcb		
Vial #	: 1-51	Sample Type	: Unknown
Date Acquired Date Processed	: 08-01-2019 03:50:55 : 08-01-2019 04:54:00	Acquired by Processed by	: System Administrator : System Administrator

<Chromatogram>



<Peak Table>

PDA Ch1 214nm				
Peak#	Ret. Time	Area	Height	Area%
1	45.013	183701	5470	100.000
Total		183701	5470	100.000

Fig. S24: HPLC chromatogram of compound 4.



Fig. S25: HRMS of 4.



Fig. S26a: MS/MS of m/z 1428.9191 parent ion $[M+H]^+$ for compound 4.



Fig. S26b: MS/MS of m/z 1214.7532 daughter ion b_{12} for compound 4.



Fig. S27: HPLC overlay chromatogram of compounds 1, 2, 3 and 4.



. S28: Marfey's analysis of compound $\mathbf{2}$



Fig. S29: Extracted ion chromatograms of m/z 368, 370, 384 and 400 for compound 2



S30: Marfey's analysis of compound **3**



S31: Extracted ion chromatograms of m/z 368, 370, 384 and 400 for compound **3**.



S32: Marfey's analysis of compound 4



Fig. S33: Extracted ion chromatograms of m/z 368, 370, 384 and 400 for compound 4



Fig. S34: Extracted ion chromatograms of m/z 382 (-ESI) for compound ^L*allo*-Ile, ^LIle **2**, **3** and **4** using chiral LCMS



Fig. S35: NMR-VT experiment performed at 298K, 308K, 318K, and 328K for compound **1** in DMSO- d_6 at 400 MHz (Region $\delta 6.7 - 9.1$).

Minimum Inhibitory Concentration of compound against Mycobacterium tuberculosis

Data entry In vitro Mycobacterium tuberculosis Screening

In house 3, Page No **129**, Dated; 21-05-2015

Organism	:	Mycobacterium tuberculosis H ₃₇ Rv
Media	:	Middlebrook 7H9 broth supplemented with 10% ADC
Method	:	Microdilution assay/REMA method
Stock Concentration	:	10 mg/ml
Starting concentration	1:	64 µg/ml

S. No.	Compound Code	MIC in µg/ml
1.	VPS-P1-B (Velutibol-A)	32
2.	Rifampicin	0.06

Fig. S36: Anti-tubercular screening report of compound 1